Estados Unidos - inglês - NLM (National Library of Medicine)

international medication systems, limited - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 1 mg in 1 ml - morphine sulfate is indicated for the relief of severe pain. it is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. it is likewise effective in the control of postoperative pain. the use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction,severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. tolerance develops to the analgesic effects and increasingly higher doses

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine sulfate pentahydrate, quantity: 30 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride - indications as at 7 july 2020: dbl morphine sulfate injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. dbl morphine sulfate injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine sulfate pentahydrate, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - indications as at 7 july 2020: dbl morphine sulfate injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. dbl morphine sulfate injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine sulfate pentahydrate, quantity: 15 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - indications as at 7 july 2020: dbl morphine sulfate injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. dbl morphine sulfate injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - indications as at 7 july 2020: dbl morphine sulfate injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. dbl morphine sulfate injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Estados Unidos - inglês - NLM (National Library of Medicine)

precision dose inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate oral solution is indicated for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. morphine sulfate oral solution 100 mg per 5 ml (20 mg/ml) is indicated for the relief of acute and chronic pain in opioid-tolerant patients. limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. morphine sulfate oral solution is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.4)] . - acute or severe bronchial asthma in an unmonitored setting or in the absence of re

Estados Unidos - inglês - NLM (National Library of Medicine)

atlantic biologicals corp. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate oral solution is indicated for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. morphine sulfate oral solution 100 mg per 5 ml (20 mg/ml) is indicated for the relief of acute and chronic pain in opioid-tolerant patients. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2) ], reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: morphine sulfate oral solution is contraindicated in patients with: risk summary prolonged use of opioid analgesics during pregnancy can cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.5)]. there are no available data with morphine sulfate oral solution in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. published s

Estados Unidos - inglês - NLM (National Library of Medicine)

atlantic biologicals corp. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate oral solution is indicated for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. morphine sulfate oral solution 100 mg per 5 ml (20 mg/ml) is indicated for the relief of acute and chronic pain in opioid-tolerant patients. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2) ], reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: morphine sulfate oral solution is contraindicated in patients with: risk summary prolonged use of opioid analgesics during pregnancy can cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.5)]. there are no available data with morphine sulfate oral solution in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. published

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - tablet, modified release - excipient ingredients: povidone; hypromellose; magnesium stearate; hyetellose; purified talc; lactose monohydrate; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 400 - for the management of severe pain where other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. is not indicated as an as-needed (prn) analgesia.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate, quantity: 100 mg - tablet, modified release - excipient ingredients: hyetellose; povidone; hypromellose; magnesium stearate; purified talc; titanium dioxide; iron oxide black; macrogol 400 - for the management of severe pain where other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. is not indicated as an as-needed (prn) analgesia.